A Systematic Review and Meta-analysis on the Occurrence of Biomarker Mutation in Colorectal Cancer among the Asian Population

Table 2

Major characteristics of the prevalence of BRAF screening studies that were included in the meta-analysis.

S/N	Author	Year	Location	Male, (%)	Age	Sample size	Tumour stage (early stage)	Tumour stage (late-stage)	Tumour location (colon)	Tumour location (rectum)	Tumour grade (poorly differentiated)	Tumour grade (moderately differentiated)	Tumour grade (well-differentiated)	Method	Total BRAF mutation (%)
1	Bagadi et al., 2012 [27]	2012	India	74	56 (23-93)	100	22.5	77.5	78	22	NR	NR	NR	Sequencing	17
2	Eachkoti et al., 2018 [77]	2018	India	49		57	36.8	63.2	52.6	47.4	8.8	54.4	36.8	Sequencing	21.1
3	Fu et al., 2019 [78]	2019	China	60	60 (14-96)	5495	NR	NR	50.1	0.499	6.5	0.713	24.4	HRMS	2.8
4	Mohammadi Asl et al., 2014 [79]	2014	Iran	55	44.ynn (40-50)	80	NR	NR	NR	NR	NR	NR	NR	PCR-FFLP/S	46.3
5	He et al., 2020 [36]	2020	China	62	59 (26-83)	194	4.1	83	72.6	27.3	45.9	NR	NR	Sequencing	11.9
6	Hsieh et al., 2012 [37]	2012	Taiwan	NR	NR	182	NR	NR	NR	NR	NR	NR	NR	Sequencing	1.1
7	Jauhri et al., 2017a [39]	2017	India	61	NR	112	23.2	76.8	82.1	17.9	NR	NR	NR	Sequencing	7.1
8	Kaji et al., 2011 [41]	2011	Japan	35		98	NR	NR	NR	NR	NR	NR	NR	NR	0
9	Karbalaie Niya et al., 2016 [42]	2016	Iran	57	NR	1000	NR	NR	NR	NR	16.4	38.4	43.9	HRMS	0
10	Korphaisarn et al., 2019 [14]	2019	Thailand	57	64 (30-89)	108	24.1	75.9	82.4	17.6	6.5	86.1	4.6	PNAMPCR	1.9
11	Kwon et al., 2011 [43]	2011	South Korea	60		92	0	100	56.5	43.5	15.2	67.4	12	PNAMPCR/S	3.3
12	Mohamed Suhaimi et al., 2015 [48]	2015	Singapore	55	58.5 (26-74)	44	50	40.9	54.5	45.5	NR	NR	NR	HRM-S	11.4
13	Nagakubo et al., 2019 [52]	2019	Japan	NR	NR	50	NR	NR	NR	NR	NR	NR	NR	SS	6
14	Nguyen et al., 2021 [53]	2021	Vietnam	56		151	76.2	19.2	68.9	31.1	10.2	36.2	53.2	SS	2.6
15	Rozek et al., 2010 [80]	2010	Israel	5	NR	1297	NR	NR	NR	NR	NR	NR	NR	Sequencing	5
16	Saxena et al., 2018 [81]	2018	India	68	64 (26-90)	65	60	40	NR	NR	23.1	50.8	26.2	Immunohistochemistry	4.6
17	Shimada et al., 2018 [82]	2018	Japan	59	NR	111	NR	NR	NR	NR	NR	NR	NR	NGS	6.3
18	Siraj et al., 2014 [58]	2014	Saudi Arabia	51	NR	770	44.5	49.2	NR	NR	12.1	76.6	9.6	PCR/sequencing	2.2
19	Song et al., 2020 [59]	2020	China	61	NR	2356	44.8	45.2	NR	NR	18.7	NR	81.3	Sequencing	1
20	Taniguchi et al., 2020 [83]	2020	Japan	NR	66	325	NR	NR	NR	NR	NR	NR	NR	Sequencing	10.5
21	Taniguchi et al., 2018 [63]	2018	Japan	59	64 (26-89)	302	26.8	73.2	53	47	9.6	NR	NR	Sequencing	6
22	Vilkin et al., 2009 [84]	2009	Israel	47		128	54.9	45.1	NR	NR	25.1	54.6	20.3	Sequencing	18.8
23	Wang et al., 2017 [85]	2017	China	NR	NR	1694	NR	NR	NR	NR	NR	NR	NR	Sequencing	4.2
24	Warsinggih et al., 2020 [86]	2020	Indonesia	46		43	NR	NR	67.4	32.6	44.2	34.9	20.9	Sequencing	14
25	Yari et al., 2020 [67]	2020	Iran	NR	NR	100	NR	NR	NR	NR	NR	NR	NR	Sequencing	7
26	Yip et al., 2013 [68]	2013	Malaysia	65	NR	44	51.2	48.8	68.3	31.7	7.3	82.9	9.8	Sequencing	2.3
27	Zhang et al., 2020 [87]	2020	China	60	NR	480	18.8	81.3	44	56	21.5	NR	NR	Sequencing	4
28	Zhang et al., 2015 [73]	2015	China	59	62.1 (18-96)	1110	19.1	80.9	50.7	49.3	7.5	73.5	19	PCR-SS	3.1
29	Zhu et al., 2020 [74]	2020	China	70	NR	53	37.7	62.3	NR	NR	NR	NR	NR	Sequencing	11.3

N: number; NR: not reported. Percentage of all samples, age is presented in years ((/median (range/IQR)/range). HRMS: high resolution melting- (HRM-) sequencing; HRMA/P: high resolution melting assay/pyrosequencing; PNAM/PCR and PNAM/PCR/S: peptide nucleic acid-mediated polymerase chain reaction/sequencing; IHC: immunohistochemistry; SS: Sanger sequencing.